Day: December 16, 2022

Glycerin Market to Reach $5.13 Billion by 2028 | Indonesia Exported Glycerin Worth $461 Million Followed by Germany ($270M) and Malaysia ($243M)

Written by Customer Service on December 16, 2022. Posted in Mergers And Acquisitions.

Global glycerin market size was valued at USD 3.3 billion in 2021, and it is expected to reach a value of USD 5.13 billion by 2028, at a CAGR of 5.3% over the forecast period (2022-2028). Westford, USA, Dec. 16, 2022 (GLOBE NEWSWIRE) — The majority of glycerin is used in the production of soap and other personal care products, but it is also used as a food additive, sweetener, and antifreeze. SkyQuest’s analysis of the glycerin market is based on our global experience working with companies in this space. We have deep understanding of the unique characteristics of this market, including the definitive role played by Malaysia. As a result, we are able to provide insights and perspectives that helps our clients make informed decisions. The glycerin market is fascinating due its arbitrage-driven structure and geographically...

Global Marine Vessel Market to Reach Valuation of $191.25 Billion by 2028 | Market is Facing Headwinds from Overcapacity, Sluggish Demand and Rising Costs

Written by Customer Service on December 16, 2022. Posted in Mergers And Acquisitions.

Global marine vessel market was valued at USD 165.12 billion in 2021, and it is expected to reach a value of USD 191.25 billion by 2028, at a CAGR of 1.61% over the forecast period (2022–2028). Westford, USA, Dec. 16, 2022 (GLOBE NEWSWIRE) — In recent years, the marine vessel market has been one of the most dynamic and innovative market globally. The outlook for the sector is positive, with SkyQuest forecasting significant growth in the coming years. The maritime sector is forecast to grow at a compound annual growth rate (CAGR) of 4.2% between 2022 and 2028. This growth will be driven by a number of factors, including the continued expansion of global trade, the ongoing need for energy and resources, and the growing demand for maritime transportation services. Looking ahead, our industry analyst believes that the maritime industry...

uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B

Written by Customer Service on December 16, 2022. Posted in Public Companies.

If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia B LEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL (ASX: CSL), has received a positive opinion recommending conditional marketing authorization (CMA) for etranacogene dezaparvovec from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Etranacogene dezaparvovec is a one-time gene therapy for the treatment of appropriate adults with hemophilia B that reduces the rate of annual bleeds after a single infusion.1,2 uniQure conducted the multi-year clinical development...

Dassault Aviation: Europe’s Future Combat Air System: on the way to the first flight

Written by Customer Service on December 16, 2022. Posted in Public Companies.

Europe’s Future Combat Air System: on the way to the first flightIndustry awarded € 3.2 bn by France, Germany, Spain FCAS Phase 1B Contract for R&T and flying Demonstrators Global Design@AirbusDefence @dassault_onair @IndraCompany @EumetE Saint-Cloud, Munich, Madrid, 16 December 2022 – On behalf of the governments of France, Germany and Spain, the French General Directorate for Armament (DGA) has awarded to Dassault Aviation, Airbus, Indra, EUMET and their industrial partners the contract for the Demonstrator Phase 1B of the Future Combat Air System (FCAS). This landmark contract, amounting to € 3.2 billion, will cover work on the FCAS demonstrator and its components for about three and a half years. Dassault Aviation, Airbus, Indra and EUMET welcome this major step forward that reflects the determination of France, Germany and...

PhenixFIN Corporation Announces Fiscal Fourth Quarter 2022 Financial Results

Written by Customer Service on December 16, 2022. Posted in Earnings Releases And Operating Results.

NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) — PhenixFIN Corporation (NASDAQ: PFX) (the “Company”), a publicly traded business development company, today announced its financial results for the fiscal fourth quarter of 2022. HighlightsFourth quarter total investment income was $5.1 million; net investment income of $1.9 million Net asset value (NAV) of $120.8 million, or $57.49 per share as of September 30, 2022, vs. $57.08 per share as of September 30, 2021 Secured a 3-year $50 million credit facility with Woodforest National Bank as lead lender (SOFR + 2.90%) Notice of Redemption issued for the $22.5 million 6.125% unsecured notes due March 30, 2023 Repurchased 16.5% of shares outstanding in Fiscal Year 2022 Weighted average yield to maturity of 10.85% on yield-oriented investments FlexFIN continues to grow with over...

The Ensign Group, Inc. Increases Quarterly Dividend to $0.0575 Per Share

Written by Customer Service on December 16, 2022. Posted in Dividend Reports And Estimates.

SAN JUAN CAPISTRANO, California, Dec. 16, 2022 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (NASDAQ: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it has declared a quarterly cash dividend of $0.0575 per share of Ensign common stock, payable on or before January 31, 2023, to shareholders of record as of December 31, 2022. “We are pleased to announce our twentieth consecutive annual dividend increase, which reflects our strong market position and continued commitment to return value to our shareholders,” commented Barry Port, Ensign’s Chief Executive Officer. “We look forward to continued growth and are optimistic...

Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology

Written by Customer Service on December 16, 2022. Posted in Mergers And Acquisitions.

Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platform Cancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Grail (acquired by Illumina), Exact Sciences, Guardant Health and more Expects ACT to contribute US$25-30 million in revenues in 2023 Positions Prenetics solidly within the US$80+ billion global precision oncology market Acquisition expected to complete on or around December 30, 2022, subject to normal closing conditionsLONDON and HONG KONG, Dec. 16, 2022 (GLOBE NEWSWIRE) — Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that it is acquiring a majority stake in ACT Genomics Holdings Company Limited...

QPR Software Plc’s financial reporting in 2023

Written by Customer Service on December 16, 2022. Posted in Public Companies.

QPR SOFTWARE PLC STOCK EXCHANGE RELEASE 16 December 2022 at 13 pm EETIn this stock exchange release, QPR Software Plc provides its financial calendar for 2023, which includes the planned publication dates of its financial reports.QPR will publish three interim reports in 2023: • Interim report January–March 2023 on Wednesday 3 May 2023 • Half-year financial report January-June 2023 on Friday 21 July 2023 • Interim report January-September 2023 on Friday 20 October 2023 QPR Software’s financial statement bulletin, activity report, audit report, and report on the corporate governance system for the financial year 2022 will be published on Friday, February 10, 2023. QPR’s annual report 2022 will be published on March 20, 2023, and QPR’s annual general meeting 2023 is scheduled...

Melco Announces Final Award of Gaming Concession

Written by Customer Service on December 16, 2022. Posted in Public Companies.

MACAU, Dec. 16, 2022 (GLOBE NEWSWIRE) — Melco Resorts & Entertainment Limited (Nasdaq: MLCO) (“Melco” or the “Company”), a developer, owner and operator of integrated resort facilities in Asia and Europe, today announces that the Macau government has awarded a ten-year concession to operate games of fortune and chance in casinos in Macau (“Concession”) to Melco Resorts (Macau) Limited, a subsidiary of the Company. The term of the Concession commences on January 1, 2023 and ends on December 31, 2032. Mr. Lawrence Ho, Chairman and Chief Executive Officer of Melco commented, “On behalf of Melco, we are honored and grateful for the Macau SAR government’s granting of the ten-year gaming concession to the Company, and we are thankful for the government’s running of a smooth and transparent process. “Melco pledges its commitment...

Alvotech Completes $59.7 Million Private Placement

Written by Customer Service on December 16, 2022. Posted in Public Companies.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced completion of a private placement of approximately US$59.7 million, at current exchange rates, of subordinated convertible bonds (the “Bonds”), convertible into new fully paid ordinary shares of Alvotech. Alvotech intends to use the majority of the net proceeds from the private placement offering to replace a US$50 million unsecured subordinated loan from Alvogen (“Alvogen Facility”) which was announced on November 16, 2022. In accordance with the Alvogen Facility agreement, associated rights by Alvogen to procure warrants representing up to 4.0% of Alvotech’s ordinary share capital will no longer apply. Alvotech will issue the Bonds in an aggregate principal amount of approximately...

Day: December 16, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice